Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
Olaparib + Cediranib/Ceralasertib for Advanced Breast Cancer
Recruiting1 awardPhase 2
Houston, Texas
This trial studies olaparib with cediranib or AZD6738 as a treatment for patients with BRCA mutated breast cancer that has spread to other places in the body.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.